Lp(a)-Reducing Agent Pelacarsen Misses the Mark in Phase 3—Now What?
In the authors' words
This journal does not let us republish the full abstract. Here are the two sentences Pipette selected, quoted from it. Read the rest at the publisher.
Main result
This Medical News article discusses the top-line results from the Lp(a)HORIZON trial, which investigated lipoprotein(a) lowering to reduce major adverse cardiovascular events.
Appeared: Sunday, October 18. JAMA. Peer-reviewed journal.